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OBJECTIVE—In skeletal muscle, insulin stimulates glucose
transport activity three- to fourfold, and a large part of this
stimulation is associated with a net translocation of GLUT4 from
an intracellular compartment to the cell surface. We examined
the extent to which insulin or the AMP-activated protein kinase
activator AICAR can lead to a stimulation of the exocytosis limb
of the GLUT4 translocation pathway and thereby account for the
net increase in glucose transport activity.
RESEARCH DESIGN AND METHODS—Using a biotinylated
photoafﬁnity label, we tagged endogenous GLUT4 and studied
the kinetics of exocytosis of the tagged protein in rat and human
skeletal muscle in response to insulin or AICAR. Isolated ep-
itrochlearis muscles were obtained from male Wistar rats. Vastus
lateralis skeletal muscle strips were prepared from open muscle
biopsies obtained from six healthy men (age 39  11 years and
BMI 25.8  0.8 kg/m
2).
RESULTS—In rat epitrochlearis muscle, insulin exposure leads
to a sixfold stimulation of the GLUT4 exocytosis rate (with basal
and insulin-stimulated rate constants of 0.010 and 0.067 min
1,
respectively). In human vastus lateralis muscle, insulin stimu-
lates GLUT4 translocation by a similar sixfold increase in the
exocytosis rate constant (with basal and insulin-stimulated rate
constants of 0.011 and 0.075 min
1, respectively). In contrast,
AICAR treatment does not markedly increase exocytosis in
either rat or human muscle.
CONCLUSIONS—Insulin stimulation of the GLUT4 exocytosis
rate constant is sufﬁcient to account for most of the observed
increase in glucose transport activity in rat and human muscle.
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mpairments in skeletal muscle glucose uptake occur
in type 2 diabetes (1–4) and are associated with
defects in GLUT4 translocation rather than a change
in the total amount of GLUT4 protein (2,5). These
changes are also associated with defects in cell signaling
(6,7). However, in healthy normal glucose-tolerant rela-
tives of type 2 diabetic patients, impairments in skeletal
muscle insulin-stimulated glucose transport activity occur
without alterations in the phosphorylation of Akt or its
downstream target protein AS160 (8). In rodents, marked
impairments in insulin signaling to glycogen metabolism
occur as a consequence of skeletal muscle GLUT4 knock-
out (9), suggesting that defects in GLUT4 trafﬁc have the
potential to feed back and inhibit early steps in insulin
signaling. Changes in GLUT4 translocation may be one of
the earliest molecular defects in type 2 diabetes (8). Thus,
it is important to determine molecular mechanisms that
link insulin signaling to GLUT4 translocation.
Skeletal muscle represents the major site of postpran-
dial glucose disposal (10); therefore, kinetic studies of
GLUT4 trafﬁcking in this tissue are important to determin-
ing the major sites of insulin action, particularly because
GLUT4-trafﬁcking defects have been observed in skeletal
muscle from type 2 diabetic patients (11,12). In adipose
tissue, GLUT4-trafﬁcking kinetic studies have identiﬁed
the exocytic limb of the translocation pathway as the
major site of insulin action (13–16). In contrast to adipo-
cytes, skeletal muscle is a complex tissue, with diverse
GLUT4 storage sites, including multiple perinuclear and
satellite compartments that are close to the transverse
tubules (17–19). Moreover, skeletal muscle GLUT4 trans-
location and glucose transport are increased in response
to a wide range of stimulatory factors including contrac-
tion, changes in calcium release, and changes in the
cellular energy status and AMP levels (19).
To determine the extent to which insulin action stimu-
lates the exocytosis limb of the GLUT4 translocation
pathway, and thereby account for the net increase in
translocation, we have developed new methods for study-
ing GLUT4 translocation in rat epitrochlearis and human
vastus lateralis skeletal muscle. We have speciﬁcally ex-
amined whether the stimulation of exocytosis following
exposure to insulin or the AMP precursor analogue AICAR
(5-aminoimidazole-4-carboxamide ribonucleoside) can
fully account for associated increases in glucose transport
activity.
RESEARCH DESIGN AND METHODS
Epitrochlearis muscle isolation. Male Wistar rats (150–200 g) were ob-
tained from B&K Universal, Sollentuna, Sweden. Animals were housed under
a 12-h light/12-h dark cycle and had free access to water and standard rodent
chow and were fasted (5 h) before each experiment. The Stockholm North
Animal Ethics Committee approved all studies. Rats were anesthetized with
an intraperitoneal injection of sodium pentobarbital (5 mg/100 g body wt i.p.).
Isolated epitrochlearis muscles were incubated at 30°C. All incubation media
were prepared from pregassed (95% O2/5% CO2) Krebs-Henseleit buffer (KHB)
containing 5 mmol/l HEPES and 0.1% BSA (radioimmunoassay grade). The gas
phase in the vials was maintained at 95% O2/5% CO2.
Open muscle biopsy. Six healthy men with no known family history of
metabolic disorder (aged 39  11 years and BMI 25.8  0.8 kg/m
2) volunteered
for the muscle biopsy procedure. All subjects were instructed to avoid
strenuous exercise for 72 h before the muscle biopsy. The subjects reported
to the laboratory after an overnight fast. The study protocol was approved by
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received from all subjects before participation.
Open biopsies were taken from vastus lateralis muscle under local anes-
thesia (5 mg/ml mepivakain chloride), as previously described (20,11). Muscle
strips were dissected, mounted on Plexiglass clamps, and incubated in vitro in
pregassed (95% O2 and 5% CO2) KHB in a shaking water bath at 35°C.
Glucose transport. Isolated rat epitrochlearis muscles were incubated in
pregassed KHB containing 15 mmol/l mannitol and 5 mmol/l glucose for 20
min. Muscles were transferred to fresh KHB and incubated with either 120
nmol/l insulin or 1 mmol/l AICAR for the times speciﬁed in the ﬁgure legends.
Muscles were then transferred to fresh KHB containing 20 mmol/l mannitol
and incubated for 10 min to rinse excess glucose, followed by incubation for
12 min in KHB containing 5 mmol/l 3-O-methyl-D-[
3H]-glucose (800 Ci/mmol)
and 15 mmol/l [
14C]-mannitol (53 Ci/mmol). Muscles were blotted of excess
ﬂuid, frozen in liquid nitrogen, and stored at 80°C. Glucose transport rate
was analyzed by the accumulation of intracellular 3-O-methyl [
3H] glucose
(21).
Akt and AMP-activated protein kinase phosphorylation. Muscles were
homogenized and protein phosphorylation was determined as previously
described (22) by Western blot analysis using anti–phospho-Ser473 Akt,
anti–phospho-Thr172 AMP-activated protein kinase (AMPK)-, or anti–
phospho-Ser79 acetyl CoA carboxylase antibodies (from Cell Signaling
Laboratories).
GP15 photoafﬁnity tagging of GLUT4. A biotin tag was introduced into
GLUT4 using a photolabeling procedure. Muscles were incubated at 18°C for
8 min in the presence of 1 mmol/l glucose-photolabel-15 (GP15) (23,24) and
then irradiated for 2 min in a Rayonet photochemical reactor (Southern New
England Ultraviolet, Branford, CT) using 300-nm lamps. Muscles were rinsed
four times in ice-cold PBS and either frozen directly in liquid nitrogen or
transferred for continued incubation. Muscles were stored at 80°C until
analysis. GP15-tagged GLUT4 was identiﬁed as described (12) for the similar
but shorter photoafﬁnity labeling compound Bio-LC-ATB-BMPA.
Steady-state internalization of GLUT4. For internalization-trafﬁcking time
course experiments, rat epitrochlearis muscles were ﬁrst incubated in KHB
containing 15 mmol/l mannitol and 5 mmol/l glucose at 30°C for 20 min.
Muscles were then transferred to fresh KHB and incubated with either 120
nmol/l insulin for 30 min or 1 mmol/l AICAR for 50 min. Insulin and AICAR
concentrations were maintained at these constant levels throughout the
remainder of the protocol. Before GP15 photoafﬁnity tagging of GLUT4,
muscles were transferred to fresh KHB containing 20 mmol/l mannitol for 10
min to rinse away glucose. KHB was cooled to 18°C during photoafﬁnity
tagging to slow transporter recycling.
After irradiation, muscles were washed once in KHB at 18°C to remove
excess GP15 label and were then transferred to fresh KHB and incubated at
30°C to initiate internalization of the biotin-tagged GLUT4. At the speciﬁed
internalization time points, 80 g/ml avidin (Pierce Chemical, Rockford, IL)
was added for 6 min at 30°C to block transporters that were still at the cell
surface. Muscles were rinsed four times in ice-cold PBS, frozen directly in
liquid nitrogen, and stored at 80°C until analysis. The maximum signal of
GLUT4, which internalized and escaped the surface quenching, was deter-
mined in each experiment from insulin- or AICAR-stimulated samples that
were returned to the basal state and allowed to internalize the biotinylated
GLUT4 for 60 min. Initial GLUT4 signal was determined in samples incubated
without the addition of avidin.
Exocytosis of GLUT4. For exocytosis experiments, human vastus lateralis
muscles or rat epitrochlearis muscles were incubated at 35 or 30°C, respec-
tively. After 20 min, muscles were transferred to fresh KHB containing 12
nmol/l insulin. Insulin-stimulated muscles were photoafﬁnity labeled with
GP15 and subsequently washed with MES buffer (KHB with MES replacing
HEPES), pH 6.0, for 5 min to terminate insulin stimulation. Muscles were
maintained in KHB for 40 min to obtain maximal internalization. To begin the
determination of exocytosis, 160 g/ml avidin was added for 6 min. Thereaf-
ter, muscles were transferred to KHB with or without 120 nmol/l insulin or 1
mmol/l AICAR for speciﬁed times. The rate of loss of the internal transporters
as they became quenched by the surface avidin was determined at the
indicated time points.
Curve ﬁtting and analysis of rate constants. Values for net internalization
of GLUT4 under steady-state conditions were curve ﬁtted using a two-
parameter equation: F  (1.0  E).exp(k.t)  E, where F is the fraction of
GLUT4 remaining at the surface, E is the equilibrium position for internaliza-
tion, k is the net internalization–rate constant, and t is time. The contributions
from exocytosis (kex) and endocytosis (ken) to the progress to equilibrium
were determined using the following equation: F  {kex  ken.exp[t.(kex 
ken)]}/(kex  ken) (11). Values for unidirectional exocytosis of GLUT4 were
curve ﬁtted to a single exponential equation: F  exp( k.t), where F is the
fraction of GLUT4 remaining internal, and k is the exocytosis rate constant,
and t is time. Individual experiments were analyzed, and the resulting
parameters were used to obtain mean and SE values, which were then
compared in unpaired t tests. Differences were considered signiﬁcant at P 
0.05. Analysis and curve ﬁtting were carried out using Graphpad Prism
software.
RESULTS
Comparison of insulin and AICAR treatment on glu-
cose transport activity in rat epitrochlearis muscle.
Insulin stimulation of epitrochlearis muscle leads to a
rapid increase in glucose transport activity that reaches an
equilibrium level of stimulation three- to fourfold above
basal levels within 20 min (Fig. 1A). Conversely, in re-
sponse to AICAR, the maximum level of stimulation is
slower in onset and only reaches a level of stimulation
2.5-fold above basal after 60 min. The maximum levels of
stimulation by insulin and AICAR are maintained at a
steady state for a further 30 min. At the steady state, the
stimulation of glucose transport activity by insulin is
slightly higher than that induced by AICAR. We assessed
whether changes in the kinetics of GLUT4 trafﬁcking
induced by these treatments could account for the differ-
ences observed in glucose transport activity. We used an
FIG. 1. Comparison of the stimulation of glucose transport and cell-
surface GLUT4 levels by insulin and AICAR in rat epitrochlearis
muscle. A: Transport rates were determined from measurements of
3-O-methyl-D-[
3H]-glucose uptake into muscle specimens incubated for
the indicated times in the presence of 120 nmol/l insulin or 1 mmol/l
AICAR. Results are means  SE of six experiments. B: Levels of cell
surface GLUT4 were determined by labeling muscle strips with GP15
photolabel following 30 min of incubation with 120 nmol/l insulin (f)
and 50 min of incubation with 1 mmol/l AICAR (). Labeled samples
were solubilized, and the biotin-tagged GLUT4 was precipitated on
immobilized streptavidin, resolved on SDS-PAGE gels, and then de-
tected and quantiﬁed by blotting with GLUT4 antibody. Results are
means  SE of six (insulin) and ﬁve (AICAR) experiments.
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the cell surface. GP15 consists of a glucose moiety that is
recognized by the GLUT4 binding site and a biotin tag that
can interact with avidin or streptavidin. The biotin and
glucose moieties are separated by a very long spacer that
allows access of avidin to the tagged transporter (23,24).
We found that the higher increase in glucose transport
activity following insulin stimulation versus AICAR stim-
ulation is matched by a slightly but insigniﬁcantly higher
level of steady-state GLUT4 labeling by GP15 (Fig. 1B).
In addition to the observed differences in the rate of
onset of the maximal stimulation of glucose transport
activity, insulin and AICAR produce a markedly different
pattern of early signaling changes in the intermediate
serine kinases, Akt/protein kinase B, and AMPK. Insulin,
but not AICAR, action leads to a marked stimulation of Akt
phosphorylation (Fig. 2A). Conversely, AICAR, but not
insulin, action leads to a robust stimulation of AMPK
phosphorylation (Fig. 2B) and the downstream AMPK
substrate acetylCoA carboxylase (Fig. 2C). The slight
increase in AMPK phosphorylation following insulin treat-
ment is not signiﬁcant over a series of experiments or
when corrected for total AMPK levels. The maximally
rapid time frame for insulin-stimulated increase in Akt
phosphorylation was within 2–10 min, and the AICAR-
stimulated increase in AMPK phosphorylation also oc-
curred rapidly and reached a maximum within 30 min (25)
(H.K.R.K., A.V.C., H.A.K., J.Y., F.K., H.W.-H., J.R.Z., G.D.H.,
unpublished data). This increase is more rapid than the
increase to maximal levels of glucose transport activity
(Fig. 1A).
Steady-state GLUT4 trafﬁcking in insulin- and
AICAR-stimulated rat epitrochlearis muscle. The
maintenance of steady-state and maximal levels of glucose
transport activity and cell-surface GLUT4 content (Fig. 1)
could be due to a pulse of GLUT4 translocation, which is
then followed by a cessation of subsequent movement as
the cell signaling processes continue. Alternatively,
GLUT4 could continue to recycle under steady-state con-
ditions, and the cell-surface GLUT4 level could be main-
tained by a net balance of a fast exocytosis and a fast
endocytosis rate of translocation. In adipocytes, GLUT4
appears to continuously recycle during insulin-stimulated
signaling (13,26,27). Therefore, we determined whether
GLUT4 continues to recycle in rat skeletal muscle. The
rate of net internalization of GP15-tagged GLUT4 under
steady-state stimulation by either insulin or AICAR has
been measured by separating the GLUT4 that remains at
the cell surface from that which has been internalized. To
do this, avidin is added to the muscle specimens after
labeling. The initial cell-surface labeling (ﬁrst lane in Fig.
3A) is reduced by the avidin addition at the beginning of
the time course (second lane in Fig. 3A). At subsequent
times of incubation, GLUT4 internalizes and escapes the
extracellular avidin. This gives a steady rise in the internal
signal from the tagged GLUT4 at 5–60 min (Fig. 3A). The
steady-state insulin stimulation is associated with rapid
internalization that is almost complete within 10 min. The
ﬁnal level of net internalization occurs when approxi-
mately half the initial cell-surface GLUT4 is internalized
(Fig. 3B). At this point, the exocytosis and endocytosis are
balanced to maintain the surface levels of GLUT4. Con-
versely, the steady-state AICAR stimulation is associated
with a slower initial net internalization, particularly over
the ﬁrst 5 min where the fraction of internalization is lower
than that occurring in insulin-stimulated muscle. Addition-
ally, the rate of progress to the equilibrium level is not
complete until 30–60 min (Fig. 3B). This is associated with
a slower rate constant for net internalization between
AICAR- and insulin-stimulated muscles (0.059 vs. 0.134
min
1, respectively). Furthermore, the ﬁnal equilibrium
level of internalized GLUT4 is reached at a lower cell-
surface fraction (0.29) than that associated with insulin
stimulation (0.52) (Fig. 3C). Further analysis of the steady-
state data (Fig. 3D) indicates that AICAR treatment is
associated with a slower endocytosis rate constant (0.042
vs. 0.068 min
1) and a much slower exocytosis rate
constant (0.017 vs. 0.067 min
1). These kinetic parameters
predict that the levels of glucose transport activity and
cell-surface GLUT4 in AICAR-treated muscle will be 55% of
those in insulin-treated muscle. These values are in rea-
sonable agreement with data presented in Fig. 1.
The steady-state data reveal important differences in the
kinetics of GLUT4 trafﬁcking following insulin or AICAR
treatment. However, the net internalization of GLUT4
under these conditions is a complex kinetic process that
involves both endocytosis of GLUT4 and its recycling
(exocytosis). To further address whether AICAR- or insu-
lin-stimulated glucose transport and signaling activities
occur by a convergent mechanism, we simpliﬁed our study
design in subsequent experiments to only measure the
exocytosis rate constant.
Exocytosis of GLUT4 in insulin- and AICAR-stimu-
lated rat epitrochlearis muscle. To more directly mea-
sure the kinetic parameters of exocytosis, a procedure
was adopted in which GP15-tagged GLUT4 was internal-
ized and then the unidirectional return to the cell surface
was monitored. To internalize the GP15-tagged GLUT4, it
was necessary to ﬁrst label insulin-stimulated muscle and
then reverse the stimulated state by washing with a low pH
buffer that disassociates insulin from its receptor (28). To
check that this procedure is adequately effective, we
monitored the reversal of Akt phosphorylation (Fig. 2A).
Akt phosphorylation is reduced toward basal levels within
100 min. The return to basal levels of phosphorylation is
incomplete; however, it is only necessary that the reversal
process is sufﬁcient to allow a detectable portion of
rat epitrochlearis
p-Akt Ser473
p-ACC Ser79
p-AMPK Thr172
human skeletal muscle
Basal
AICAR
Insulin 1
Insulin 2
Recovery 1
Recovery 2
p-Akt Ser473
rat epitrochlearis
rat epitrochlearis B
A
C
D
FIG. 2. Phospho-protein signaling in rat epitrochlearis and human
vastus lateralis muscle. Immunoblots of p–Akt Ser473 (A), p–AMPK
Thr172 (B), and p–CoA carboxylase Ser79 (C) in lysates of rat
epitrochlearis and p–Akt Ser 473 (D) in human vastus lateralis muscle.
Muscle lysates were resolved on SDS-PAGE, transferred to nitrocel-
lulose membranes, and incubated overnight with phospho-speciﬁc
antibodies. Immunoreactive proteins were visualized by enhanced
chemiluminescence. Conditions are as follows: basal, initial basal;
insulin 1, 12 nmol/l insulin stimulation for 52 min; recovery 1, 102-min
recovery after removal of initial insulin stimulation; insulin 2, restimu-
lation with 120 nmol/l insulin for 50 min after recovery; AICAR,
restimulation with 1 mmol/l AICAR for 50 min after recovery; and
recovery 2, 162-min recovery after removal of initial insulin stimula-
tion. The ﬁgure includes representative immunoblots from six inde-
pendent experiments.
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adequate (Fig. 4A).
The movement of GLUT4 from the internal compart-
ment to the plasma membrane was rendered unidirec-
tional by the addition of avidin at the cell exterior
throughout the time course used to study the exocytosis.
As the GLUT4 reaches the cell surface, its signal is
quenched by avidin binding. The GLUT4 signal that re-
mains in the cell, therefore, represents the fraction of
GLUT4 remaining internally, and this decreases with time
(Fig. 4A). This allows curve ﬁtting to a single exponential
function even when the scatter in the data points is quite
large (Fig. 4B). The scatter is an unavoidable consequence
of working with single muscle samples for each time
course data point. Insulin treatment increases the rate
constant for exocytosis sixfold (0.010 in the basal state to
0.067 min
1 in the insulin-stimulated state; P  0.05).
However, AICAR treatment does not signiﬁcantly increase
the apparent exocytosis rate constant. The rate constant is
0.012 min
1, which is close to the basal value. This
exocytosis rate constant is in reasonable agreement with
the steady-state exocytosis rate constant in AICAR-treated
cells (0.017 min
1).
A limitation of the ﬁtting of a single exponential function
is that it assumes that the internal GLUT4 signal decreases
continuously to zero. However, it may not (29,30). In the
basal and AICAR-treated cells, the release of GLUT4 may
occur in a pulse and the internal GLUT4 signal may reach
a plateau point at which no further release occurs. Thus,
AICAR may stimulate a portion of the internal GLUT4 to
be released. The ﬁtting method we have employed may
lead to an underestimate of the rate constant for this
partial release. Unfortunately, the data are insufﬁciently
precise for further analysis of this possibility. The more
limited exocytosis response to AICAR cannot be due to a
slow onset in AMPK activation, as we have compared
basal and AICAR at times of exocytosis up to 120 min.
Furthermore, the steady-state parameters were obtained
following an extensive treatment with AICAR. Taking into
consideration both the steady-state and the direct exocy-
tosis measurements, we cannot exclude the possibility of
an AICAR-mediated increase in exocytosis; however, this
effect is clearly smaller, or more limited as a pulse of
release of GLUT4, than that occurring in insulin-treated
muscle.
Exocytosis of GLUT4 in insulin- and AICAR-stimu-
lated human vastus lateralis muscle. The exocytosis
approach characterized in the isolated rat epitrochlearis
muscle system was applied to human muscle strips. We
conﬁrmed that the reversal procedure adopted for the rat
epitrochlearis was also applicable to human muscle (Fig.
2B). A comparison of basal and insulin-treated muscle
FIG. 3. Internalization of GP15-tagged GLUT4 under steady-state stimulation with insulin or AICAR in rat epitrochlearis muscle. Muscle strips
were incubated with 120 nmol/l insulin or 1 mmol/l AICAR and then labeled with GP15. The GP15-tagged GLUT4 was then allowed to internalize
for the indicated times. To separately identify internalized GLUT4, avidin was added to the medium to quench the signal from cell surface–located
GLUT4. Internal GLUT4 was then solubilized, and the biotin-tagged GLUT4 was precipitated on immobilized streptavidin, resolved on SDS-PAGE
gels, and detected and quantiﬁed by immunoblot analysis with a GLUT4 antibody. A: Representative blots. init, initial labeling without avidin
addition. B: By comparison of the initial GLUT4 signal with the signal at the indicated times, the level of cell-surface GLUT4 was calculated. C
and D: Curve ﬁtting to data from separate experiments was used to calculate rate constants as described in RESEARCH DESIGN AND METHODS. The
curves in B were computed from the average rate constants in C. Results are the means  SE of four experiments. *P < 0.05.
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GLUT4 movement out of the internal compartment and
toward the cell surface (Fig. 5A). Curve-ﬁtting analysis
(Fig. 5B) and analysis of separate experiments (Fig. 5C)
revealed that the exocytosis rate constant was increased
six- to sevenfold (from 0.011 to 0.075 min
1). These
rate-constant values and the six- to sevenfold stimulation
are very similar to the changes occurring in rat epitroch-
learis muscle. This suggests that the same kinetic process
is present, even under conditions in which the levels of
glucose transport are quite different. The six- to sevenfold
increase in glucose transport activity does not occur in
human muscle, but this is not necessarily inconsistent
with a large change in GLUT4 translocation, as additional
factors may inﬂuence the glucose transport activity. The
effect of AICAR on GLUT4 exocytosis in human muscle is
less clear, partly because of the large scatter in data points
derived from the samples available in the study (Fig. 5B).
Calculation of the exocytosis rate constants (0.017 min
1,
Fig. 5C) indicated that there may be some slight, but
statistically insigniﬁcant, stimulation of exocytosis above
basal levels following AICAR treatment of the muscle
strips. The observed exocytosis rate constant is, however,
identical to that derived from the steady-state exocytosis
experiment in AICAR-treated rat muscle.
DISCUSSION
Analysis of the trafﬁcking kinetic data parameters for
GLUT4 translocation in skeletal muscle is essential to
resolve the site of convergence with the insulin-signaling
steps. If the site of insulin action is more fully resolved,
this would help deﬁne where defects in GLUT4 trafﬁc
occur in insulin-resistant states and type 2 diabetes. By
applying and extending use of our GLUT4-labeling tech-
nique, we have provided some of the ﬁrst evidence that
GLUT4 exocytosis in rat and human skeletal muscle is the
major site of insulin action and that the magnitude of the
stimulation of the exocytosis rate constant is sufﬁcient to
account for the observed insulin stimulation of glucose
transport.
Studies on relatively simpler cell-culture systems have
revealed that GLUT4 trafﬁcs through multiple compart-
ments (31,32). In skeletal muscle, additional complexities
in the trafﬁcking route occur because of the large ﬁbrous
cell structures and the presence of a more complex
transverse-tubule network of membranes. Recent studies
on green ﬂuorescent protein–tagged GLUT4 in skeletal
muscle have highlighted the importance of the transverse-
tubule system and have led to the hypothesis that GLUT4
is not translocated over long distances in skeletal muscle
but is recruited from GLUT4 satellite compartments local-
ized close to the transverse tubules (17,18). Our photola-
beling approach is complementary to studies on GFP-
GLUT4, because we tag endogenous GLUT4, rather than
expressed recombinant protein. However, the approach
does not provide information on any potential differences
in trafﬁcking at the sarcolemma or the transverse tubules.
Previous autoradiography studies using a tritiated version
of a GLUT4 photolabel have provided evidence that the
label does penetrate and label GLUT4 in the transverse-
FIG. 4. Exocytosis of GP15-tagged GLUT4 in rat epitrochlearis muscle. Muscle speci-
mens were incubated with 12 nmol/l insulin and labeled with GP15. Insulin action was
then terminated by washing with a pH 6.0 buffer, and the tagged GLUT4 was allowed to
internalize for 40 min. Muscle specimens were maintained in the basal state or
stimulated with either 120 nmol/l insulin or 1 mmol/l AICAR for the indicated times.
Avidin was added at the cell surface throughout the restimulation time courses; this
reduced the signal for GLUT4 that exocytosed to the cell surface, thereby reducing the
signal from internal GLUT4. The remaining internal GLUT4 was then solubilized, and
the biotin-tagged GLUT4 was precipitated on immobilized streptavidin, resolved on
SDS-PAGE gels, and detected and quantiﬁed by immunoblot analysis with a GLUT4
antibody. A: Representative blots. C: Curve ﬁtting for internal GLUT4 was carried out
for the basal , insulin, and AICAR treatments and data from separate experiments were used to calculate rate constants as described in RESEARCH
DESIGN AND METHODS. B: The curves were computed from the average rate constants in C. Results are means  SE. Data are derived from seven,
ﬁve, and three experiments for basal, insulin, and AICAR treatments, respectively. Basal experiments had at least three time points, but these
were varied to allow comparison with early and late time points for the insulin or AICAR stimulations. *P < 0.05.
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molecules as large as a fragment antigen binding of an
antibody can permeate into transverse-tubule spaces in
heart muscle (34).
The six- to sevenfold stimulation of the GLUT4 exocy-
tosis rate in the present study is greater than the fold
stimulation of glucose transport. This effect is consistent
with data on cell-surface GLUT4 labeling in rat (35) and
human (12) skeletal muscle. This may occur because
glucose transport is dependent on additional transporters
such as GLUT1 that respond less effectively to insulin.
Changes in GLUT4 endocytosis and storage will also
inﬂuence the level of stimulation of transport activity. The
absolute values of the rate constants obtained from rat
(0.01 for basal and 0.067 min
1 for insulin at 30°C) and
human (0.011 and 0.075 min
1 at 37°C) skeletal muscle
studies are remarkably close to adipose cell studies. For
example, basal and insulin-stimulated rate constants for
GLUT4 exocytosis in 3T3-L1 adipocytes are 0.01 and 0.09
min
1, respectively, at 37°C (27). When the GP15 photola-
bel in rat adipocytes was used, slightly higher values were
obtained (23). The similarity of these rate constants sug-
gests that the same fundamental process rate limits
GLUT4 movement in these diverse systems and that this
process is relatively unaltered by divergent cell architec-
ture and membrane tubule complexities in these differing
cell types.
Our studies on the AICAR compound are less clear.
There are several technical problems associated with its
use, including its slow onset of action. Even when GLUT4
exocytosis is studied over 120 min, there is no clear
evidence that this process is stimulated. In cardiac myo-
cytes, AMPK activation following hypoxia, mitochondrial
inhibition (36), or metformin treatment (37) is associated
with a reduction in GLUT4 endocytosis. Mitochondrial
inhibition and a combination of AICAR treatment and PKC
stimulation also lead to inhibition of GLUT4 internaliza-
tion in L6 muscle cells (38). We ﬁnd that the initial rate of
net internalization and endocytosis of GLUT4 in rat skel-
etal muscle is also reduced, but these changes do not
reach statistical signiﬁcance. The reduction in net inter-
nalization that is evident at early time points is masked in
the steady-state experiments by the progress to a lower
equilibrium level for the equilibration of the GP15-tagged
GLUT4 during AICAR treatment. The endocytosis of
GLUT4 is always a more difﬁcult kinetic parameter to
obtain and interpret than the unidirectional exocytosis
parameter. This is because internalization is a net process,
involving both endocytosis and re-exocytosis, and some
recycling of GLUT4 will inevitably occur. These limitations
may account for some of the controversies that surround
the issue of whether insulin markedly reduces GLUT4
endocytosis (16,39,40).
Whether the observed 50% reduction in GLUT4 net
internalization is sufﬁcient to account for the full magni-
tude of the AICAR stimulation of glucose transport (a two-
to threefold stimulation) is incompletely resolved in this
study. The slow onset of the increase in glucose transport
is also consistent with a slowing of GLUT4 endocytosis.
Our data suggest that a single site of convergence of
FIG. 5. Exocytosis of GP15-tagged GLUT4 in human vastus lateralis muscle. Muscle
strips were incubated with 12 nmol/l insulin and then labeled with GP15. Insulin action
was then terminated by washing with a pH 6.0 buffer, and the tagged GLUT4 was allowed
to internalize for 40 min. The strips were then maintained in the basal state or
stimulated with either 120 nmol/l insulin or 1 mmol/l AICAR for the indicated times.
Avidin was added at the cell surface throughout the restimulation time courses; this
reduced the signal for GLUT4 that exocytosed to the cell surface, thereby reducing the
signal from internal GLUT4. The remaining internal GLUT4 was then solubilized and the
biotin-tagged GLUT4 was precipitated on immobilized streptavidin, resolved on SDS-
PAGE gels, and detected and quantiﬁed by immunoblot analysis with a GLUT4 antibody.
A: Representative blots. C: Curve ﬁtting was carried out for the basal, insulin, and
AICAR treatments, and data from separate experiments were used to calculate rate constants as described in RESEARCH DESIGN AND METHODS. B: The
curves were computed from the average rate constants in C. Results are means  SE. Where no error bar is shown, n  2. Data are derived from
four, four, and two experiments for basal, insulin, or AICAR treatment, respectively. In basal experiments, time points were varied to allow
comparison with early and late time points for the insulin and AICAR stimulations. *P < 0.05.
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ate such as AS160 (7,41–43) cannot fully and simulta-
neously account for regulation of GLUT4 trafﬁc at the level
of both exocytosis and endocytosis. Indeed, AS160 action
is reported to be localized to the exocytosis rather than the
endocytosis arm of GLUT4 trafﬁc (40).
The steady-state recycling experiments are of interest
and mechanistic importance because they show that in
muscle, GLUT4 continues to recycle in both the insulin-
and AICAR-stimulated states. In contrast to earlier (44,45),
but not later, versions of the translocation hypothesis (13),
GLUT4 is not released as a transitory pulse to the cell
surface where it would then be resident while the stimulus
remains. Instead, GLUT4 continues to recycle even when
the stimulus is maintained (13,27). However, the observed
recycling could be consistent with a variant of the pulse
model in which GLUT4 is released in a pulse from a
reservoir compartment to the cell surface and then on to
the endosome system, within which it continues to recycle
while the stimulus remains (29,30).
In conclusion, our demonstration that exocytosis is the
major site of insulin action on GLUT4 trafﬁc in rat and
human skeletal muscle suggests that a focus on this limb
of the GLUT4 trafﬁc pathway in insulin-resistant condi-
tions such as type 2 diabetes will be necessary and
appropriate to resolve defects in glucose metabolism in
future studies. Because of the technical challenges and
limitations described above, the photolabeling approach
will only give a partial and incomplete analysis in future
studies. Nevertheless, the approach described is comple-
mentary to more dynamic studies in which GLUT4 is
analyzed at a detailed subcellular level (18).
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